Investigational New Drugs **12:** 347–350, 1994.

CONTENTS VOL. 12, 1994

Review

Multidrug resistance in cancer chemotherapy – N.H. Patel, M.L. Rothenberg 1

Preclinical Study

Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines – K.G. Steube, D. Grunicke, H.G. Drexler 15

Phase I Study

Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy – V. Ganju, J.H. Edmonson, J.C. Buckner 25

Phase II Studies

Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas – E.S. Casper, M.R. Green, D.P. Kelsen, R.T. Heelan, T.D. Brown, C.D. Flombaum, B. Trochanowski, P.G. Tarassoff 29

Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancer – W.D.Y. Quan, Jr., G.E. Dean, G. Lieskovsky, M.S. Mitchell, R.A. Kempf 35

A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study – R.B. Weiss, B.L. Peterson, S.L. Allen, S.M. Browning, D.B. Duggan, C.A. Schiffer 41

Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck – M.S. Kies, D. Grinblatt, M. Runge-Morris, R. Blough, A. Watkins, S. Taylor IV 45

FIVB plus GM-CSF in metastatic colorectal cancer – C.I. Falkson, G. Falkson, H.C. Falkson, A. Uys, S. Keren-Rosenberg 49

Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study – B. Barlogie, J. Crowley, S.E. Salmon, J. Bonnet, J.K. Weick, K. Hayden 53

5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma – P.J. Loehrer, Sr., D. Harry, R.T. Chlebowski 57

Phase II trial of Echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study – D.H. Shevrin, T.E. Lad, P. Guinan, L.J. Kilton, A. Greenburg, P. Johnson, R.R. Blough, H. Hoyer 65

Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. A Southwest Oncology Group study – S.A. Taylor, B.A. Blumenstein, R.L. Stephens, E.D. Crawford, B. Pistone, J.B. Hill 67

Announcement 71

Instructions for authors 73

Review

Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma – G. Rodriguez 75

Preclinical Studies

Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR – M. Mariani, L. Capolongo, A. Suarato, A. Bargiotti, N. Mongelli, M. Grandi, W.T. Beck 93

Evaluation of the methemoglobinemia associated with sulofenur – D.C. Molthrop Jr., R.H. Wheeler, K.M. Hall, J.T. Prchal 99

Phase I Studies

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome) – P. Guaglianone, K. Chan,

E. DelaFlor-Weiss, R. Hanisch, S. Jeffers, D. Sharma, F. Muggia 103

Weekly gemcitabine in advanced or metastatic solid tumors: A clinical phase I study – C.F. Pollera, A. Ceribelli, M. Crecco, F. Calabresi 111

Phase II Studies

Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors: A Southwest Oncology Group study – V. Gupta, E.B. Thompson, D. Stock-Novack, S.E. Salmon, H.I. Pierce, J.D. Bonnet, D. Chilton, J. Beckord 121

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer: A Southwest Oncology Group study – J.O. Atiba, S.J. Green, H.E. Hynes, C.K. Osborne, T.P. Miller, M. Davidner 129

Phase II trial of intravenous melphalan in advanced colorectal carcinoma – D.F. Moore Jr., R. Pazdur, J.L. Abbruzzese 133

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma – J. Berlin, A.C. King, K. Tutsch, J.W. Findlay, P. Kohler, M. Collier, N.J. Clendeninn, G. Wilding 137

Phase II trial of topotecan in patients with advanced renal cell carcinoma – T.M. Law, D.H. Ilson, R.J. Motzer 143

Phase II evaluation of merbarone in renal cell carcinoma – R.C. Flanigan, J.H. Saiers, M. Wolf, E.H. Kraut, A.Y. Smith, B. Blumenstein, E.D. Crawford 147

Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885 – A.Y. Chang, Z.N. Tu, G.T. Bryan, J.M. Kirkwood, M.M. Oken, D.L. Trump 151

Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study – A. Hantel, C.M. Tangen, J.S. Macdonald, S.P. Richman, R.P. Pugh, T. Pollock 155

Phase II trial of piroxantrone in gastric carcinoma. A Southwest Oncology Group study – A. Hantel, C. Tangen, W.L. Gluck, J.S. Macdonald 159

Phase II study of fludarabine phosphate for gastric adenocarcinoma: An Illinois Cancer Center trial – L.J. Kilton, J.B. Ashenhurst, J.L. Wade III, R.L. Schilsky, G. Shiomoto, R.R. Blough, S.L. French, A.B. Benson III 163

Instructions for authors 167

Preclinical Studies

Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines *in vitro* – B.T. Hill, R.D.H. Whelan, S.A. Shellard, S. McClean, L.K. Hosking 169

In vitro comparison of cytotoxic effects of crotoxin against three human tumors and a normal human epidermal keratinocyte cell line – C.J. Rudd, L.J. Viskatis, J.C. Vidal, M.A. Etcheverry 183

Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol – D. Fan, G. Poste, C. Seid, L.E. Earnest, T. Bull, R.K. Clyne, I.J. Fidler 185

Phase I Studies

Intraperitoneal 5-fluoro-2′-deoxyuridine with escalating doses of leucovorin: Pharmacology and clinical tolerance – F.M. Muggia, A. Tulpule, A. Retzios, F. Chen, S. Jeffers, C.G. Leichman, L. Leichman, C.P. Spears, K.K. Chan 197

Pyrazine diazohydroxide (NSC-361456): Phase I clinical and pharmacokinetic studies – M.V. Dhodapkar, R.L. Richardson, J.M. Reid, M.M. Ames 207

Phase II Studies

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas – J.E. Romaguera, M.A. Rodriguez, F.B. Hagemeister, P. McLaughlin, F. Swan, D.F. Moore, Jr., A.H. Sarris, A. Younes, D. Hill, F. Cabanillas 217

Phase I/II study of cisplatin, 5-fluorouracil and α-interferon for recurrent carcinoma of the head and neck – M.H. Huber, M. Shirinian, S.M. Lippman, I.W. Dimery, R.A. Frankenthaler, W.K. Hong 223

Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma: A phase II study – A. Testolin, G. Recher, V. Cristoferi, G. Gasparini 231

Phase II study of deoxyspergualin in metastatic breast cancer – K. Dhingra, V. Valero, L. Gutierrez, R. Theriault, D. Booser, F. Holmes, A. Buzdar, G. Fraschini, G. Hortobagyi 235

Phase II clinical trial of didemnin B in previously treated small cell lung cancer – D.M. Shin, P.Y. Holoye, A. Forman, R. Winn, R. Perez-Soler, S. Dakhil, J. Rosenthal, M.N. Raber, W.K. Hong 243

Phase II trial of fotemustine in patients with metastatic malignant melanoma – C.I. Falkson, G. Falkson, H.C. Falkson 251

Trimetrexate in advanced hormone-refractory prostate cancer: An ECOG phase II trial – R.S. Witte, B.Y. Yeap, D.L. Trump 255

A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma – M.R. Grever, J. Benedetti, S.P. Balcerzak, S.A. Taylor, T.P. Miller, S.R. Dakhil 259

Phase II trial of piroxantrone in metastatic gastric adenocarcinoma – R. Pazdur, B. Bready, A.J. Scalzo, J.E. Brandof, D.R. Close, S. Kolbye, R.J. Winn 263

Phase II study of amonafide in gastric adenocarcinoma: An Illinois Cancer Center Trial – M.R. Mullane, R.L. Schilsky, R.B. Carroll, J.L. Wade III, L.J. Kilton, R.R. Blough, A. Bauman, S.L. French, A.B. Benson III 267

Instructions for authors 271

Preclinical Studies

Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer – D.L. Trump, J.A. Hathorn, L.B. Grochow, D. Spriggs, M.L. Eble, J.A. Hohneker 273–276

Phase I study of mitonafide with a 3-day administration schedule: Early interruption due to severe central nervous system toxicity – E. Díaz-Rubio, M. Martín, J.M. López-Vega, A. Casado, A. Benavides 277–281

Phase I Studies

Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer – G.T. Budd, P. Herzog, R.M. Bukowski 283–287

Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP–16 – L.N. Petersen, P.B. Jensen, B.S. Sørensen, S.A. Engelholm, M. Spang-Thomsen 289–297

Phase II Studies

High dose aminothiadiazole in advanced colorectal cancer. *An Illinois Cancer Center phase II trial* – G.Y. Locker, L. Kilton, J.D. Khandekar, T.E. Lad, R.H. Knop, K. Albain, R. Blough, S. French, A.B. Benson, III 299–301

Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U–80,244) – J.D. Jonkman-de Vries, M.J.A. de Graaff-Teulen, R.E.C. Henrar, J.J. Kettenes-van den Bosch, A. Bult, J.H. Beijnen 303–314

Phase II study of elsamitrucin in non-small cell lung cancer – G. Goss, F. Letendre, D. Stewart, F. Shepherd, L. Schacter, P. Hoogendoorn, E. Eisenhauer 315–317

Phase II trial of PALA and 6–methylmercaptopurine riboside (MMPR) in combination with 5–fluorouracil in advanced pancreatic cancer – I. Redei, F. Green, J.P. Hoffman, L.M. Weiner, R. Scher, P.J. O'Dwyer 319–321

Phase II study of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma – T. Murray Law, P. Mencel, R.J. Motzer 323–325

Phase II study of carboplatin and edatrexate (10–EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck – M.H. Huber, I.W. Dimery, S.E. Benner, S.M. Lippman, M. Shirinian, B. Esparaz, D. Frenning, C. Guillory-Perez, W.K. Hong 327–331

Phase II trial of piroxantrone in metastatic breast cancer. *A Southwest Oncology Group study* – P. M. Ravdin, S. Green, J.H. Doroshow, S. Martino 333–336

Hepatoma/merbarone. *A Southwest Oncology Group study* – E.A. Poplin, C.M. Tangen, W.H. Harvey, J.S. Macdonald 337–340

Phase II study of edatrexate in advanced head and neck cancer. *A Southwest Oncology Group study* – J.P. Kuebler, J. Benedetti, D.E. Schuller, J. Ensley, S.M. Grunberg, M.J. Muirhead, K.E. Richert-Boe, M.E. Marshall 341–344

Phase II trial of 6-thioguanine in advanced renal cell carcinoma. *An Ilinois Cancer Center study* – D.H. Shevrin, L.J. Kilton, T.E. Lad, M. Mullane, B. Esparaz, R. Knop, J. Egner, P. Johnson, R. Blough, S. French, A.B. Benson, III 345–346

Contents Volume 12, 1994 347–350
Author Index 351–352
Instructions for authors 353–354